共 50 条
N-terminal modifications leading to peptide ORL1 partial agonists and antagonists
被引:14
|作者:
Judd, AK
Kaushanskaya, A
Tuttle, DJ
Sanchez, A
Khroyan, T
Polgar, W
Toll, L
机构:
[1] SynVax Inc, N Logan, UT 84341 USA
[2] Stanford Univ, Med Ctr, Beckman Ctr, Prot & Nucleic Acid Facil, Palo Alto, CA 94304 USA
[3] SRI Int, Menlo Pk, CA 94025 USA
来源:
JOURNAL OF PEPTIDE RESEARCH
|
2003年
/
62卷
/
05期
关键词:
affinity;
agonists;
antagonists;
nociceptin;
orphanin;
peptides;
D O I:
10.1034/j.1399-3011.2003.00077.x
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that is the endogenous ligand for the G protein-coupled receptor (opioid receptor like 1, ORL1), a member of the opioid receptor family. Although it is clear that this receptor system is involved in a variety of physiological functions, including analgesia, the precise actions of N/OFQ remain largely uncharacterized. One reason for this has been limited high affinity ligands to ORL1, and particularly the lack of availability of useful specific antagonists. Herein we describe the pharmacological activity of a series of N-terminally modified hexapeptides with high affinity for ORL1. These compounds were tested for binding affinity using [H-3]N/OFQ binding to human ORL1 in CHO cells, and functional activity by measuring stimulation of [S-35]GTPgammaS binding in CHO cell membranes. The N-terminal modifications have produced compounds that maintained very high receptor affinity, but led to significant changes in intrinsic activity. One compound, pentanoyl-RYYRWR-NH2, with barely measurable agonist activity was tested in vivo. It was found to possess modest analgesic activity, but it was unable to block the morphine modulatory activity of N/OFQ.
引用
收藏
页码:191 / 198
页数:8
相关论文